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Two new studies reveal novel DNA-binding properties of MeCP2, mutations of which cause Rett
syndrome. Baker et al. report critical roles for the AT-hook domain of MeCP2 in chromatin organi-
zation and clinical features of Rett syndrome. Melle´n et al. find the methyl-CpG-binding domain of
MeCP2 interacts with hydroxymethyl-CpG.Epigenetic mechanisms, including DNA
methylation, histone modifications, and
chromatin organization, allow eukaryotic
cells to define genes and regulate gene
expression beyond simple genomic DNA
sequence. DNA methylation is critical for
development, differentiation, and function
of most multicellular organisms. Methyl-
CpG-binding protein 2 (MeCP2) is the
founding member of the methyl-CpG-
binding domain (MBD) protein family that
binds to 5-methylcytosine (5mC) (Lewis
et al., 1992). MeCP2 is highly abundant
in mammalian neuronal nuclei, and over-
expression, deletion, or various point
mutations of the MECP2 gene cause
Rett syndrome (RTT) (Amir et al., 1999).
Understanding MeCP2 function and its
underlying mechanism has clinical signifi-
cance andmay reveal fundamental epige-
netic regulatory mechanisms. In this and
a recent issue of Cell, Baker et al. (2013)
and Melle´n et al. (2012) report mecha-
nistic insights and clinical importance of
binding properties of MeCP2 protein
toward AT-rich DNA sequences and
toward 5-hydroxymethyl-CpG (5hmC)
DNA. Both studies suggest a critical
involvement ofMeCP2 in chromatin struc-
ture and shed new light on how MeCP2
dysfunction may contribute to RTT.
RTT, an autism spectrum disorder
(ASD), is a progressive neurodevelop-
mental disorder characterized by initial
normal development, followed by slow
brain growth, development of autistic
features, stereotypies, and seizures.940 Cell 152, February 28, 2013 ª2013 ElsevZoghbi and colleagues made the ground-
breaking discovery that RTT patients have
frequentmutations in the X-chromosome-
linked MECP2 gene (Amir et al., 1999).
Despite two decades of research, how
MeCP2 dysfunction causes RTT remains
unclear. MeCP2 was initially cloned by
Bird and colleagues as a 5mC-binding
protein (Lewis et al., 1992). Their pioneer-
ing work defined the MBD and transcrip-
tion repressor domain (TRD) of MeCP2
(Figure 1A) (Nan et al., 1997), which led
to a model that MeCP2 protein binds to
5mC and functions as a transcription
repressor (Guy et al., 2011). However,
MeCP2 is known to interact with chro-
matin, and in the brain more than half
of MeCP2 molecules reside in the
open chromatin, which have lower 5mC
levels than heterochromatin. In addition,
MeCP2 knockout mice mostly exhibit
decreased expression of many genes,
and MeCP2 overexpression mice shows
the upregulation of the same set of genes.
Thus, MeCP2 function appears to be
vastly more complex than had been
appreciated (Guy et al., 2011).
Baker et al. (2013) focus on a highly
conserved AT-hook domain within the
TRD of MeCP2 and present compell-
ing evidence for its role in chromatin
organization and disease progression
(Figure 1A). They generate male trans-
genic mice bearing either a R270X or
G273X MeCP2 mutation. Strikingly,
G273X transgenic mice display signifi-
cantly later onset and slower diseaseier Inc.progression compared to R270X trans-
genic mice (Figure 1A), resembling
features of male RTT patients with
G273fs and R270fs mutations, respec-
tively. At the molecular level, however,
MeCP2-R270X and MeCP2-G273X both
behave similarly to wild-type MeCP2 in
many respects, including localization at
heterochromatic foci and genome-wide
distribution. Both mutations disrupt the
TRD and repressor activity. Gene expres-
sion profiles are also very similar between
the two mutant mice. What then contrib-
utes to different phenotypes in these
two mutant mice? The answer is that
MeCP2-R270X, but not MeCP2-G273X,
disrupts a highly conserved AT-hook
domain, which binds to AT-rich DNA,
regardless ofCpGmethylation (Figure 1A).
MeCP2-R270X mice show significant
defects in chromatin compaction and
pericentric heterochromatin (PCH) locali-
zation of a-thalassemia mental retarda-
tion syndrome X-linked (ATRX), a chro-
matin remodeling protein that interacts
with MeCP2 (Figure 1A). The onset of
aberrant ATRX localization also coincided
with RTT-like phenotypes, further sug-
gesting an important role of ATRX in the
function and dysfunction of MeCP2.
In another study, Melle´n et al. (2012)
discover that the MBD of MeCP2 binds
to 5mC and 5hmC in vitro with similar
affinity (Figure 1A). 5hmC, a recently
discovered oxidation product of 5mC
present most abundantly in the brain
(Kriaucionis and Heintz, 2009), has been
Figure 1. MeCP2 Exhibits Multifaceted DNA-Binding Properties to Regulate Different
Chromatin States
(A) A schematic diagram of MeCP2 structure and summary of findings from three different MeCP2
mutations investigated in Baker et al. and Melle´n et al. The methyl-CpG-binding domain (MBD) of MeCP2
is involved in the interaction with 5mC, 5hmC and ATRX, whereas the AT-hook domain within the tran-
scription repressor domain (TRD) interacts with AT-rich DNA. MeCP2-R133C loses binding affinity to
5hmC, but retains 5mC-binding affinity. MeCP2-R133C binds very weakly to ATRX, and mutant cells
almost completely lose ATRX pericentric heterochromatin (PCH) localization (Nan et al., 2007). Both
MeCP2-R270X and MeCP2-G273X retain in vitro ATRX-binding affinity, but ATRX gradually loses its
localization to PCH earlier in MeCP2-R270X mutant neurons and later in MeCP2-G273X mutants. The
MeCP2 R133C phenotype is from human patients, and the mouse model remains to be examined.
(B) A schematic representation of MeCP2 in heterochromatin (compact chromatin) and euchromatin
(open chromatin) in the neuronal nucleus. In neurons, higher amounts of MeCP2 exist in euchromatin
than in heterochromatin. Histone H1, which induces highly organized and compact chromatin
structure, competes with MeCP2 in binding to linker DNA. In heterochromatin, chromatin is highly
organized, DNA is highly methylated, and 5mC-bound MeCP2 mostly interacts with repressive chromatin
remodelers and transcription repressors. In euchromatin, chromatin is less compact, DNA is more
hydroxymethylated or unmethylated, and 5hmC-bound MeCP2 mostly interacts with transcription
activators. ATRX interacts with MeCP2 and loses its localization whenMeCP2 bears amutation disrupting
the AT-hook domain in the TRD.postulated to function as an intermediate
of active DNA demethylation and as an
independent epigenetic mark (Guo et al.,
2011b). Melle´n et al. start with quantita-
tive, genome-wide analyses of 5hmC,
5mC and gene expression in vivo. Using
an elegant approach with geneticallymodified animals, they were able to
perform RNA-seq and MeDIP analyses
from distinct neural cell types, thus
eliminating complications from cell
heterogeneity. They not only confirm early
reports of neuron-specific anticorrelation
between gene body CpG methylationCell 152,and gene expression (Guo et al., 2011a),
but also find a strikingly clear positive
correlation between gene expression
and 5hmC/5mC ratio. Probably the most
exciting result is direct mass spectro-
metric detection of MeCP2 in both
5mC- and 5hmC-bound nuclear protein
fractions. Using electrophoretic mobility
shift and surface plasmon resonance
assays, they confirm similar in vitro
binding affinity of the MBD of MeCP2
toward 5mC and 5hmC. These results
raise an important question: how does
each of these MeCP2 populations, either
5mC- or 5hmC-bound, contribute to the
development of RTT? Interestingly, the
MeCP2-R133C mutation, which causes
a milder form of RTT in patients, specifi-
cally ablates 5hmC binding but leaves
5mC binding relatively intact (Figure 1A).
Finally, a chromatin accessibility assay
shows that 5hmC is enriched in highly
accessible chromatin, which is attenu-
ated without MeCP2.
Both studies identify novel DNA-
binding features of MeCP2 protein and
together suggest a new model for the
multifaceted role of MeCP2 in neurons
depending on its genomic locations
(Figure 1B). In somatic cells, MeCP2
mostly resides in heterochromatin with
histone H1, which forms regular and
compact chromatin structure arrays. In
neurons, where the level of MeCP2 is an
order of magnitude higher, MeCP2 largely
substitutes for histone H1 and is distrib-
uted throughout the genome. MeCP2
can form complexes with either transcrip-
tion activating or suppressing factors
(Guy et al., 2011). 5hmC-bound MeCP2
in euchromatin may be coupled with tran-
scriptional activators to turn on gene
expression, whereas MeCP2 in hetero-
chromatin is likely to bind to transcrip-
tional repressors to shut down gene
expression.
Several interesting questions arise.
First, both studies support the model
that MeCP2 regulates chromatin organi-
zation, yet the exact features of chromatin
structures that are altered by MeCP2
dysfunction are not clear. Genome-wide
chromatin analyses, such as Hi-C or
ChIA-PET, combined with different
MeCP2 mutant animal models, may pro-
vide a more complete picture. Second,
what is the mechanism underlying disrup-
ted MeCP2-ATRX interaction in the RTTFebruary 28, 2013 ª2013 Elsevier Inc. 941
mouse model, despite normal in vitro
binding of mutant MeCP2 to ATRX? Third,
what is the structural basis for MeCP2
binding to 5hmC and 5mC? It is intriguing
that other MBD family members showed
no or much weaker binding to 5hmC,
although R133 is highly conserved
among the MBD family. The in vitro
binding properties of MeCP2 to 5hmC
also beg further confirmation of interac-
tion in vivo. Fourth, do posttranslational
modifications of MeCP2, which are
known to affect MeCP2 function (Guy
et al., 2011), regulate binding of MeCP2
to 5hmC and/or AT-rich DNA? Both
studies, while investigating neurons only
in the basal state, raise the possibility of
dynamic interactions between MeCP2
and different binding partners to regulate
chromatin structure, which can be
corroborated with dynamic changes of
5mC and 5hmC in neurons in response
to neuronal activity (Guo et al., 2011a,
and 2011b). Rapidly accumulating
evidence supports the contribution of942 Cell 152, February 28, 2013 ª2013 Elsevdiverse chromatin remodeling factors to
ASD. Baker et al. and Melle´n et al. high-
light the importance of incorporating
complex and dynamic chromatin struc-
tures into our understanding of RTT
and other ASDs. By identifying molecular
events triggered by MeCP2 dysfunction,
we will be able not only to identify
therapeutic targets for RTT and ASD
patients, but also to elucidate funda-
mental epigenetic regulatorymechanisms
in the brain.
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Cell division depends on sophisticated molecular machinery. However, wall-less forms of bacteria
use a much simpler mechanism that mimics spontaneous division of synthetic lipid vesicles.
Mercier et al. (2013) show that this ‘‘mechanical’’ division can be activated by increased lipid
synthesis. Conceivably, the first cells divided via this route.Cell division, even in the relatively simple
bacterial and archaeal cells, is mediated
by highly complex, elaborate molecular
machinery. However, the cell-wall-defi-
cient L forms to which many bacteria
convert when cell wall biogenesis is in-hibited, in particular by cell-wall-targeting
antibiotics, bypass these mechanisms
and instead divide via a much simpler
mechanism that involves shape perturba-
tions, including blebbing, tubulation, and
vesiculation (Errington, 2013). In this issueof Cell, Mercier et al. (2013) show that the
switch to this ‘‘biophysical’’ mode of divi-
sion can be triggered by an increased lipid
synthesis that results in an increased cell
surface to volume ratio. The first cells,
up to the stage of the last universal cellular
